Anti-CHI3L1 antibody suppresses colon cancer growth through downregulation of VEGFA and NAMPT expression.
- Published in:
- Archives of Pharmacal Research, 2025, v. 48, n. 5, p. 450, doi. 10.1007/s12272-025-01548-y
- By:
- Publication type:
- Article
Works matching IS 02536269 AND DT 2025 AND VI 48 AND IP 5
Results: 5
1
2
BTK inhibitors and next-generation BTK-targeted therapeutics for B-cell malignancies.
- Published in:
- Archives of Pharmacal Research, 2025, v. 48, n. 5, p. 426, doi. 10.1007/s12272-025-01546-0
- By:
- Publication type:
- Article
3
Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance.
- Published in:
- Archives of Pharmacal Research, 2025, v. 48, n. 5, p. 404, doi. 10.1007/s12272-025-01545-1
- By:
- Publication type:
- Article
4
Deficiency of β-arrestin2 ameliorates MASLD in mice by promoting the activation of TAK1/AMPK signaling.
- Published in:
- Archives of Pharmacal Research, 2025, v. 48, n. 5, p. 384, doi. 10.1007/s12272-025-01544-2
- By:
- Publication type:
- Article
5
RSK2 and its binding partners: an emerging signaling node in cancers.
- Published in:
- Archives of Pharmacal Research, 2025, v. 48, n. 5, p. 365, doi. 10.1007/s12272-025-01543-3
- By:
- Publication type:
- Article